Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 253 more sites in the U.S.
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Oncology Associates — Tucson, Arizona
+ 100 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease p…
Sponsor: Replimune, Inc.
NCT ID: NCT06264180
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- The Angeles Clinic and Research Institute — Los Angeles, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a …
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06585410
Locations: - Medical Dermatology Specialists — Phoenix, Arizona
- Mayo Clinic - Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Locations: - Mayo Clinic — Phoenix, Arizona
- Honor Health Research Institute — Scottsdale, Arizona
- City of Hope National Medical Center — Duarte, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Locations: - University of Arizona — Tucson, Arizona
- University of California - San Diego — La Jolla, California
- The Angeles Clinic and Research Institute- West Los Angeles — Los Angeles, California
+ 34 more sites in the U.S.
Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Locations: - Retina Consultants of Alabama — Birmingham, Alabama
- UCSD Shiley Eye Institute, Jacobs Retina Center — La Jolla, California
- Doris Stein Eye Research Center — Los Angeles, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Sponsor: IDEAYA Biosciences
NCT ID: NCT07015190
Locations: - Mayo Clinic Scottsdale - PPDS — Scottsdale, Arizona
- UCSD Moores Cancer Center — La Jolla, California
- Jules Stein Eye Institute — Los Angeles, California
+ 28 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with im…
Sponsor: Replimune, Inc.
NCT ID: NCT06581406
Locations: - HonorHealth Research Insisute — Scottsdale, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- The Angeles Clinic and Research Institute — Los Angeles, California
+ 26 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents,…
Sponsor: Immunocore Ltd
NCT ID: NCT05549297
Locations: - Mayo Clinic Arizona — Phoenix, Arizona
- Mayo Clinic Florida — Jacksonville, Florida
- Orlando Health Cancer Institute — Orlando, Florida
+ 22 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Locations: - University of Alabama at Birmingham: The Kirklin Clinic — Birmingham, Alabama
- City of Hope — Duarte, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
+ 19 more sites in the U.S.
Phase 3 Recruiting Industry
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …
Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Locations: - Mayo Clinic Hospital — Phoenix, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health-Chao Family Comprehensive Cancer Center — Orange, California
+ 16 more sites in the U.S.